Insider Selling: Cutera, Inc. (NASDAQ:CUTR) EVP Sells $64,594.60 in Stock

Cutera, Inc. (NASDAQ:CUTRGet Free Report) EVP Michael Karavitis sold 24,940 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $2.59, for a total transaction of $64,594.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Michael Karavitis also recently made the following trade(s):

  • On Tuesday, May 14th, Michael Karavitis sold 10,848 shares of Cutera stock. The stock was sold at an average price of $2.45, for a total transaction of $26,577.60.

Cutera Price Performance

NASDAQ CUTR opened at $2.22 on Friday. Cutera, Inc. has a 1-year low of $1.28 and a 1-year high of $21.41. The business’s fifty day moving average price is $2.02 and its 200-day moving average price is $2.47.

Cutera (NASDAQ:CUTRGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The medical device company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.05). The firm had revenue of $38.79 million for the quarter, compared to analysts’ expectations of $37.17 million. During the same quarter in the previous year, the business earned ($1.26) EPS. Research analysts anticipate that Cutera, Inc. will post -5.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its holdings in Cutera by 112.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,363 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 4,430 shares during the period. Fox Run Management L.L.C. grew its position in shares of Cutera by 43.8% during the third quarter. Fox Run Management L.L.C. now owns 15,130 shares of the medical device company’s stock worth $91,000 after purchasing an additional 4,607 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Cutera by 7.1% during the 1st quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock valued at $111,000 after purchasing an additional 5,017 shares during the period. Gamco Investors INC. ET AL lifted its holdings in Cutera by 0.6% in the 3rd quarter. Gamco Investors INC. ET AL now owns 1,144,646 shares of the medical device company’s stock worth $6,891,000 after purchasing an additional 7,040 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Cutera in the 3rd quarter worth approximately $43,000. 90.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Stephens restated an “overweight” rating and issued a $10.00 price objective on shares of Cutera in a report on Friday, March 22nd. StockNews.com upgraded shares of Cutera to a “sell” rating in a report on Friday, May 10th. Finally, William Blair upgraded shares of Cutera from an “underperform” rating to a “market perform” rating in a report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $12.67.

Check Out Our Latest Research Report on CUTR

Cutera Company Profile

(Get Free Report)

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.

Recommended Stories

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.